Non-viral vesicle composing of low-molecular weight polyethylenimine-conjugated stearic acid-g-chitosan oligosaccharide (CSOSA-g-PEI) was synthesized for gene delivery and therapy. The synthesized CSOSA-g-PEI had good ion-buffer capabilities and DNA-binding capacity, which could form positively charged nano-sized particles (100-150 nm) with plasmid DNA; in vitro gene transfection tests demonstrated that CSOSA-g-PEI presented much lower cytotoxicity and corresponding transfection efficiency in comparison with Lipofectamine 2000 in both human cancer cells (Hela and MCF-7) . The gene transfection of CSOSA-g-PEI/pDNA could be further enhanced in the presence of serum or by adding arginine during incubation of CSOSA-g-PEI micelles with plasmid DNA. The biodistribution experiments demonstrated CSOSA-g-PEI conjugate highly localized in the tumor tissue and indicated a persistently increased accumulation. In vivo antitumor activity results showed that CSOSA-g-PEI/plasmid pigment epitheliumderived factor formulation could effectively suppress the tumor growth (above 60% tumor inhibition) without systematic toxicity against animal body after intravenous injection.
INTRODUCTION
Gene therapy is playing an increased pivotal role in the treatment of genetic and acquired diseases that are currently intractable. In fact, the considerable difficulty for gene therapy is how to obtain an effective gene delivery in vivo. Generally, an ideal gene delivery system should satisfy the following requirements: it should be easy to use and formulate; should be biocompatible and biodegradable; should have high transfection efficiencies in a wide range of cell types, without undesired nonimmunogenic and toxic side reactions; and should be able to release the genetic drug in a sustained or controlled manner. Two main types of vectors used in gene therapy are based on viral or nonviral gene delivery systems. In light of the problem of security and immunogenicity caused by viral vectors, a number of non-viral vectors have been introduced as alternatives for gene delivery; for example, chitosan, 1,2 poly (L-lysine) 3, 4 and polyethylenimine (PEI) [5] [6] [7] [8] [9] have been widely used as gene carriers. To gain high-level transfection activity, gene vector should be characterized by great membrane permeability, rapid intracellular uptake and satisfying ion-buffer flexibility. Of all polycations, chitosan and its derivatives is one of the safest gene carriers in vitro and in vivo. However, the transfection efficiency is still not satisfied based on this kind of gene delivery. PEI, a wellcharacterized cationic polymer with the high charge-density potential, provides high transfection efficiency and high levels of transgene expression in a range of mammalian cell types owing tothe proton sponge effect. 7, 10 Even so, it is note worthy that high molecular weight PEI, such as commercial PEI (Mw ¼ 25KDa), shows high cell cytotoxicity. It is also generally believed that low-molecular-weight PEI has advantages such as low cytotoxicity, but poor transfection efficiency compared with the highermolecular-weight PEI. In response, many studies have proved that organic macromolecule decorated with lower-molecularweight PEI showed lower cytotoxicity and higher transfection efficiency. 9 Another major stumbling block for most gene therapies, including tumors, is the limited and inefficient biological drug contribution. Oncogenesis involves numerous genetic defects that render neoplastic cells capable of growing, invading and eventually metastasizing. One effective alternative of potential tumor therapeutics is endogenous biologicals, which could solve the problems confronted with current cytotoxic agents such as drug resistance and side toxicity. Pigment epithelium-derived factor (PEDF), expressed as a 50-kDa secreted glycoprotein, is a serine protease superfamily member. 11 It has a highly conservative sequence and unique molecular structure, with neurotrophy, inhibiting angiogenesis, antitumor and a variety of functions. It was found that chitosan microparticles encapsulating PEDF plasmid resulted in a decrease in primary tumor growth, reduced establishment of lung metastases in an orthotopic metastatic model of osteosarcoma. 12 Overexpression of PEDF was found to significantly inhibit tumor growth and vessel formation in G361 nude mice xenografts. 13 PEDF is therefore a promising novel therapeutic agent for treatment of patients with certain types of cancer.
In our previous studies, stearic acid-grafted chitosan oligosaccharide (CSOSA), synthesized via the reaction of the carboxyl group of stearic acid with the amine group of chitosan oligosaccharide (CSO) in the presence of a catalyst, had been shown to have faster internalization ability into tumor cells than that of CSO nanoparticles. Amphiphilic stearic acid-g-oligosaccharide (CSOSA) micelles has been presented as an excellent candidate for antitumor drug 14 or gene delivery carrier. 15 In this paper, lower molecular polyethylenimine (PEI 800) was conjugated to CSOSA as a novel polycationic gene carriers, in order to improve the gene transfection efficiency level of pDNA mediated by CSOSA micelles. On the basis of their physicochemical properties, the in vitro transfection activities and in vivo antitumor activities of CSOSA-g-PEI/pDNA were investigated.
RESULTS

Synthesis and characterization of CSOSA-g-PEI conjugate
A multi-step reaction was performed for the synthesis of polyethylenimine-conjugated stearic acid-g-chitosan oligosaccharide (CSOSA-g-PEI) vector comprising PEI and CSOSA backbone. The synthesis route was shown in Figure 1a ). Firstly, CSOSA was synthesized via the reaction between amine groups of CSO and carboxyl group of stearic acid in the presence of water-soluble catalyst (EDC). The 1 H-NMR spectrum of CSOSA was shown in Figure 1b . As reported in our previous research, 12, 16 the chemical shifts at about 0.9 ppm and about 1.1 ppm were attributed to the protons of methyl and methylene of steatrate group in CSOSA, respectively. The other peaks were attributed to the protons of chitosan oligosaccharide in CSOSA. The degree of amino substitution of CSOSA investigated in this study was determined by TNBS method. The results were shown in Table 1 . The CSOSA micelles were easily prepared by dispersing CSOSA in distilled water owing to its inherent self-aggregation ability in aqueous environment.
Then, CSOSA-g-PEI conjugate was synthesized by imine reaction between aldehyde group of periodate-oxidized CSOSA and amine group of PEI (Figure 1 ). The synthesis reaction could be confirmed by the 1 H-NMR. As shown in Figure 1c , the proton peaks of PEI (-NHCH 2 CH 2 -) appeared at 3.0-2.4 ppm. Although, the same chemical shifts appeared in CSOSA, the sharp peaks at 3.0-2.4 ppm in Figure 1d could contribute to the chemical shifts of PEI (-NHCH 2 CH 2 -). Moreover, the ratio of peak area at 3.0-2.4 ppm to the peak area of methyl group in CSOSA-g-PEI was bigger than that of CSOSA. These results indicated that PEI was successfully grafted to the CSOSA chain. The degree of grafted PEI was determined by the 13 C-NMR. The peak at about 181 ppm was attributed to the carbonyl carbon of stearate group of CSOSA-g-PEI. The peak at about 38 ppm was attributed to the methylene carbon of grafted PEI of CSOSA-g-PEI (-CH 2 CH 2 NH 2 ) (data not shown). The degree of grafted PEI was then calculated according to the area of the peaks. The molecular weight of CSOSA-g-PEI was measured by GPC (Table 1 ). In addition, it was found the synthesized CSOSA-g-PEI could easily dissolve in aqueous solution at physiological pH conditions. Ion-buffer capability of CSOSA-g-PEI One prerequisite for cationic polymeric gene carrier is ion-buffer capability. According to the 'proton sponge' hypothesis, the buffer capability will help the complex to escape from the endosomes and promote transfection efficiency. 17 The higher charge density was, the better ion-buffer capability showed. As shown in Figure 2a , CSOSA-g-PEI had greater protonation capability than CSOSA as the amino groups increased by the graft of PEI. In addition, PEI appeared to exhibit better buffer capability than that of CSOSA-g-PEI because of more free prime amines. Moreover, CSOSA-g-PEI was observed to exhibit good buffering capacity in the pH range 4.0-7.5.
Characterization of CSOSA-g-PEI/pDNA complexes To gain efficient endocytosis and gene transfer, the complex should be small and compact. 18 Because of the positive charge, the CSOSA-g-PEI was used to condense the DNA-forming CSOSAg-PEI/pDNA complex nanoparticles. The complex nanoparticles with w/w ratio from 0.25 to 128 were prepared by mixing CSOSAg-PEI and DNA. The variations of Z-average hydrodynamic diameter and zeta potential of CSOSA-g-PEI/DNA complex nanoparticles against w/w ratio are shown in Figure 2b . It was clear that the Z-average hydrodynamic diameter of CSOSA-g-PEI/ pDNA complex nanoparticles decreased as the w/w ratio of CSOSA-g-PEI/pDNA complexes increased from 0.25 to 1. The decrease of hydrodynamic diameter of the complexes was owing to the condensation of complex caused by the plasmid DNA. Notice the zeta potential was increased from about À 35mV to about 30 mV as the w/w ratio increased from 0.25 to 1 (Figure 2b ). On the other hand, the hydrodynamic diameter increased slightly when the w/w ratio further increased to 128.
The DNA condensation capacity of CSOSA-g-PEI was analyzed at different weight ratios of CSOSA-g-PEI to pDNA by a gel retardation assay using an agarose gel electrophoresis. Figure 3a showed the gel retardation result of the complexes with weight ratio from 0.2 to 2. It was clear that the migration of DNA was completely retarded when the w/w ratio of CSOSA-g-PEI/pDNA complex was 0.6.
It is essential for the gene vehicle to protect DNA from enzyme degradation and to release DNA for gene expression in vitro as well as in vivo. Figure 3b showed the protection effect of CSOSA-g-PEI against plasmid DNA from DNase I (a model enzyme) degradation. As shown in Figure 3b , in contrast to the control naked DNA, CSOSA-g-PEI/pDNA complexes could protect DNA from enzymes degradation. After adding 1% SDS to the copolymer/pDNA complexes, CSOSA-g-PEI/pDNA could release DNA, which contributed the DNA expression.
Cytotoxicity of CSOSA-g-PEI MTT assay was performed in order to investigate the cytotoxicity of the synthesized conjugate. The cytotoxicity of conjugate was examined using MCF-7 and HeLa cells as model cells. As shown in Figure 3c and d, CSOSA-g-PEI exhibit good cell viability in both cell lines, whereas the cytotoxicity of Lipofectamine 2000 was found to be very high as well known. Moreover, CSOSA-g-PEI had a cell viability (450%) at the concentration of 600mg ml À 1 , which indicated more extensive dosage range of polymer for gene transfer could be selected.
In vitro transfection
In order to directly visualize the infected cells, the green fluorescent protein (GFP) assay of the complexes was estimated with pEGFP-C1 as a reporter gene. The transfection ability of the CSOSA-g-PEI/pEGFP-C1 complex with different weight ratio of CSOSA-g-PEI to pEGFP-C1 was evaluated using MCF-7 cells. Furthermore, the quantitative analysis of CSOSA-g-PEI as gene vectors was carried out in MCF-7 and HeLa cells by using reporter gene PGL-3. As shown in Figure 4c , within the range of weight ratios tested, CSOSA-g-PEI/pGL-3 complex displayed the same change in trend against different cells. The transfection efficiency increased gradually and reached a peak along with the weight ratio. CSOSA-g-PEI/pDNA reached its maximum efficiency plateau at weight ratio of about 80. And also, the transfection efficiency of CSOSA-g-PEI had no significant difference between two cell lines.
The effect of serum on the transfection was investigated by the luciferase assay. The results are shown in Figure 4d . It was confirmed that the transfection level of CSOSA-g-PEI/pDNA complex was increased in the presence of 10% serum-containing medium. However, Lipofectamine 2000/pDNA complexes gave the lower transfection activity in 10% serum. The effect of adding arginine on the transfection was investigated as well. Cationic polymeric micelles for tumor gene therapy F-Q Hu et al showed that adding arginine to CSOSA-g-PEI/pDNA complex during incubation gave an increasing transfection level.
In vivo distribution and gene expression study The recovery ratios of FITC-labeled polymer (FITC-polymer, FITC-CSSA-g-PEI) from the tested tissues were shown in Table 2 . The distribution of FITC-polymer in the tumor, liver, spleen, heart, lung, and kidney after intravenous (i.v.) injection at a dose of 30 mg FITC-polymer/kg body weight is presented in Figure 5a and b. After 3 h administration, concentration and distributed, amount of FITC-polymer in each tissue reached maximum except for that of tumor. Tumor accumulation of FITC-polymer increased persistently during 24 h after i.v. injection. Moreover, distributed amount of FITC-polymer in liver is more than that of other tissues.
Tumor-bearing mice received an i.v. injection with a dose of 25 mg plasmid DNA, and none of the mice showed signs of apparent toxicity. The bio-distribution of luciferase expression at 48 h after i.v. administration was revealed in Figure 5c . Gene expression within the heart and lung was weak following all treatments, and it was mainly attributed to the liver, kidney and tumor. Luciferase expression of CSOSA-g-PEI/DNA substantially appeared to be distributed within the tumors. However, it was on low-expression level in the tumors after treatment with Lipofectamine and naked DNA, and appeared to be very limited in the other organs.
In vivo antitumor activity of CSOSA-g-PEI/pPEDF In vivo antitumor activity of CSOSA-g-PEI/pPEDF (pigment epithelium-derived factor) was studied using A549 human pulmonary carcinoma-bearing nude mice. The change in the tumor volume was determined, and shown in Figure 6a and c. It was clear that adriamycin and CSOSA-g-PEI/ pPEDF treatments effectively suppressed the tumor growth compared with glucose treatment. Figure 6b showed that the body weight of drug-treated and untreated mice was continuously increased. It indicated that the doses of these three groups were at the range of safe treatment. However, body weights of the injection of adriamycin with 2 mg kg À 1 were lower than those treated with CSOSA-g-PEI/ pPEDF (Po0.05). This indicates the CSOSA-g-PEI/pPEDF was very safer than adriamycin.
The tumor inhibition rate of adriamycin (total DOX dosage was 14 mg kg À 1 ) was 79.73%, CSOSA-g-PEI/pPEDF with 2.5 mg kg À 1 total drug dose was 62.34%. All the tumor-inhibition values were larger than 60%, which were considered to be effective treatment.
DISCUSSION
In designing the CSOSA-g-PEI, low-molecular-weight PEI 800 was chosen for its low toxicity. CSOSA-g-PEI/DNA complexes could easily internalize into cells. There were some hydrophobic stearic branched chains near the surface of the CSOSA micelles, which enabled it to adhere to the bio-membrane and tightly enfold the liposome anchoring their alkyl chains. It was also confirmed in our previous study, CSOSA possessed rapid cellular uptake because of the hydrophobic interaction. After the grafting of PEI, the charge density was increased, and the cellular uptake ability of CSOSA-g-PEI was enhanced. Furthermore, the grafting of PEI could acidify endosomal compartments, which could efficiently release the complex nanoparticles into the cytoplasm, according to the so-called 'proton sponge mechanism'.
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It was well known that the size and zeta potentials of polycation/pDNA complexes are closely affected by its cellular uptake. 20, 21 CSOSA-g-PEI could condense pDNA into small nanoparticles, which made it easy for uptake by tumor cells. PEI modification further facilitated the formation of stable polyplexes with pDNA because of their strong positive charges at high polycation-to-DNA weight ratios. It was believed that the formation of polycation/DNA complexes was consequential for DNA stability against degradation by nucleases. The results of DNase I protection assay showed that CSOSA-g-PEI/pDNA complexes could protect pDNA from DNase I enzymolysis, which suggested that more integral pDNA could transfer to tumor cells. It was thought that the big amount of amino groups in CSOSA-g-PEI resulted in high charge density along with strong DNAcondensation ability.
GFP expression of CSOSA-g-PEI/pDNA nanoparticles in vitro was about 10-fold less efficient compared with commercial Lipofectamine 2000 after a transfection period of 24 h. However, it was found the GFP expression of CSOSA-g-PEI/pDNA nanoparticles was increased with incubation time. After 72 h of transfection, it reached its peak time. At the same time, gene transfection of Lipofectamine/pDNA decreased dramatically involved several reasons, such as its high cytotoxcity. Low cytotoxicity is undoubtedly a significant advantage of the CSOSA-g-PEI as compared with Lipofectamine. In addition, even when a high weight ratio of CSOSA-g-PEI to pDNA (weight ratio is 160) was used, the transfection efficiency was only a little lower than that at its peak time. Cellular growth, we believe, was inhibited because of high amount of copolymer material exposed to cells. It presented again that CSOSA-g-PEI had apparently lower cytotoxicity, suggesting that CSOSA-g-PEI could be a safe nonviral gene delivery vector.
The level of transfection activity was promoted by adding arginine to CSOSA-g-PEI/pDNA, which may result from that CSOSA-g-PEI/arginine/pDNA could deliver DNA to nuclear domain efficiently, and display high transfection efficiency. It also have been reported that arginine conjugated-polymers had excellent gene delivery potency. 22, 23 The possible mechanism of argininemediated enhancement of transfection efficiency was that arginine could promote the release of pDNA from the complexes during uptake into target cells. It was confirmed that the transfection level of CSOSA-g-PEI/pDNA complex increased in the presence of serum-containing medium. This may be attributed to cell viability being optimal for transfection under this circumstance. However, Lipofectamine/pDNA complexes give a lower transfection activity in complete medium containing serum, which well agreed with the literature. 24 It was suggested that Lipofectamineassociated gene delivery system was prone to combine with serum components, so that its structure had changed, whereas CSOSA-g-PEI/pDNA complex did not change substantially in the presence of serum. This indicates that CSOSA-g-PEI is more compatible for transfection in vivo than Lipofectamine.
Vascular endothelial growth factors (VEGF) are the main angiogenic cytokines studied in the last decade. 25 Currently, therapeutic angiogenesis using gene therapy to promote protracted expression of specific angiogenic proteins brings new hope as an alternative to surgery. In contrast to VEGF, pigment epithelium-derived factor (PEDF) has been demonstrated to act as a strong endogenous inhibitor of angiogenesis. 26, 27 Here, we presented that CSOSA-g-PEI/PEDF inhibited expression of VEGF against BEL7402 human hepatoma carcinoma, but little inhibition against human normal cells (Figures 6d and e) . Thus, it might be reasonable that antitumor effects of PEDF might depend on association with endothelial cell migration and vascular tube formation.
For systematic drug delivery, the particle size had an important role in the drug targeting and biodistribution according to the passive 'enhanced permeability and retention (EPR) effect'. 28 It was supposed that CSOSA-g-PEI/pDNA complex could be prone to accumulate in tumor tissues of pulmonary carcinoma-bearing mice. It was also proved that substantial tissue accumulation was observed for CSOSA-g-PEI conjugate. This result is in agreement with reports on cationic polyplexes. 29, 30 The results of in vivo gene expression of CSOSA-g-PEI/pDNA complexes showed that CSOSAg-PEI could condense plasmid DNA efficiently into nanoparticles and deliver to target vesicle, which could enable effective transfer of plasmid DNA. The accumulated CSOSA-g-PEI/pDNA in tumor tissues then could be taken up by tumor cells, and pDNA transferred into the nucleus to achieve effective gene expression, and the sufficiently expressed therapeutic protein will then lead to suppression of the tumor growth.
CONCLUSIONS
The synthesized CSOSA-g-PEI showed good ion-buffer capability, DNA-binding capacity and low toxicity. The formed gene delivery complex had nano-dimension size, good tumor distribution and expression ability. The CSOSA-g-PEI/PEDF delivery system presented effective tumor therapy without systematic toxicity via inhibition of endothelial cell migration and vascular tube formation.
MATERIALS AND METHODS Materials
Chitosan oligosaccharide (CSO, Mw ¼ 17.5 kDa, 95% deacetylated degree) was obtained by enzymatic degradation from chitosan (Mw ¼ 450.0 kDa). PEI (PEI, Mw ¼ 800 Da) and ethidium bromide were purchased from Sigma-Aldrich Chemical, St. Louis, MO, USA. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) were purchased from Shanghai Medpep, Shanghai, China. 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were purchased from Sigma Chemical, St. Louis, MO, USA. Dimethyl sulfoxide (DMSO) was purchased from Haishuo Biochemistry, Wuxi, China. Trypsin, DNase I and Dulbecco's modified eagle's medium (DMEM) were purchased from Gibco BRL, Carlsbad, CA, USA. Fetal bovine serum (FBS) was purchased from Sijiqing Biologic, Hang zhou, China. Lipofectamine 2000 was supplied from Invitrogen, Carlsbad, CA, USA. Luciferase Assay Kit was obtained from Shanghai keduan, Shanghai, China. The BCA Protein Assay Kit was purchased from Beyotime Institute of Biotechnology, China. EGFP-C1 plasmid as the GFP gene, transformed in Escherichia coli DH5a, was donated from the first Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China. PGL-3 as the luciferase reporter gene, transformed in E. coli JM109, was kindly provided by Institute of Life Science, Zhejiang University, Hangzhou, China. Pigment epitheliumderived factor (PEDF) plasmid as therapeutic gene, transformed in E. coli DH5a, was generated from muscle mRNA and cloned into a pCR-II vector by Invitrogen, USA. The integrity of plasmids was identified by agarose gel electrophoresis. Its purity and concentration were determined by ultraviolet absorbance at 260 and 280 nm. All other solvents were analytical grade.
Cell culture
Hela cells (human uterine cervix cancer cell line), MCF-7 (human breast carcinoma cell line) cells, BEL7402 (human hepatoma carcinoma) and L02 (immortalized normal human liver cell line) cells were incubated in DMEMcontaining 10% FBS (fetal bovine serum) and 1% antibiotics (penicillin and streptomycin, 100 000 U L À 1 ) at 371C and a humidified atmosphere containing 5% CO 2 .
Synthesis of CSOSA
The chemical conjugate of CSOSA was synthesized via the reaction of carboxyl group of stearic acid with amine group of CSO in the presence of 1-ethyl-3-(3-dimethylamin-opropyl) carbodiimide (EDC). Briefly, stearic acid (1.26 g) and EDC (8.27 g) were dissolved in 170 ml ethanol and chitosan oligosaccharide (CSO, 17.5 kDa) (5.02 g) was dissolved in 330 ml deionized water, respectively. Before mixing the solutions, each solution was heated up to 80 1C. The coupling reaction was carried out under vigorous stirring accompanied by drop-wise addition of stearic acid solution to CSO solution. After mixing the solutions, the reaction was performed for another 4 h at 80 1C. At the end of reaction, the solution was dialyzed (MWCO: 7 kDa, Spectrum Laboratories, Laguna Hills, CA, USA) against deionized water for 48 h with successive exchange of fresh deionized water in order to remove water-soluble by-products. Subsequently, the dialyzed solution was lyophilized. For further purification, the lyophilized product was washed with ethanol to remove the unreacted stearic acid. Finally, the product CSOSA was dispersed in deionized water and lyophilized.
Substitute degree of amino groups of CSOSA The degree of substitution, defined as the number of stearic acid groups per 100 amino groups of CSO, was determined by 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) method. After 2 ml of 4% (w/v) NaHCO3 and 2 ml of 0.1% (w/v) TNBS solution were added into 2 ml of CSOSA solution with content of 0.1 mg ml À 1 . The mixture was incubated at 37 1C for 2 h, followed by the addition of 2 ml HCl (2N). The final reaction mixture was measured at 344 nm by a ultrviolet spectrophotometer (TU-1800PC, Beijing Purkinje General Instrument, China).
Synthesis of CSOSA-g-PEI
CSOSA-g-PEI copolymer was synthesized in two steps according to previous reports 24, 31 with some modification. CSOSA (0.2 g) and sodium periodate (0.01 g) were each dissolved in sodium acetate buffer (pH 4.5) degassed with N 2 . After mixing the solutions, the reaction mixture was stirred for 2 days at 4 1C. Then, the reaction was stopped by adding ethylene glycol (10% v/v). The reaction solution was dialyzed (MWCO: 3.5 kDa, Spectrum Laboratories) against deionized water for 8 h with frequent exchange of fresh deionized water. Then, PEI solution (0.12 g PEI 800 was dissolved in 5 ml deionized water) was added dropwise to the periodateoxidized CSOSA solution. The reaction was carried out for 48 h at 4 1C under stirring with 300 rpm. At the end of reaction, the solution was treated with sodium borohydride (2.5 g NaBH 4 /g CSOSA). Finally, after dialyzing against deionized water for 24 h, the dialyzed product was lyophilized, and the CSOSA-g-PEI was received. 
Critical aggregation concentration (CAC) measurements
The critical aggregation concentration (CAC) of the synthesized CSOSA-g-PEI in deionized water was estimated by fluorescence spectroscopy using pyrene as a probe by a Fluorometer (F-2500, Hitachi, Japan). A serial of sample solution containing pyrene (6.0 Â 10 À 7 mol l À 1 ) was excited at 337 nm, and the emission spectra were recorded in the range of 340-450 nm at 10 nm min À 1 scan rate. The slit openings for excitation and emission were at 10.0 and 2.5 nm, respectively. The CMC of CSOSA-g-PEI was calculated by intensity ratio of the first to the third peak in the pyrene emission spectra.
Particle size and zeta-potential measurement
The particle size and zeta potential of CSOSA-g-PEI/pDNA complex nanoparticles were measured by dynamic light scattering using a Zetasizer (3000 HS, Malvern Instruments, Malvern, UK). CSOSA-g-PEI/pDNA complex nanoparticles were prepared in distilled water at weight ratios ranging from 0.25 to 128, and incubated 0.5 h at room temperature before measurement.
TEM observation
The morphology of CSOSA-g-PEI and CSOSA-g-PEI/pDNA complex nanoparticles was examined by transmission electronic microscopy (TEM, TECNAI 10, PHILIPS, Dutch). A drop of nanoparticle dispersions was dropped onto a copper grid without any staining. The air-dried samples were then directly observed under the transmission electronic microscopy.
Agarose gel electrophoresis experiments
Gel retardation assay was performed to confirm DNA condensation ability of the polymer. Varying amounts of CSOSA-g-PEI and of plasmid DNA (pEGFP-C1) were combined in different weight ratios, and mixed by gentle vortex. The mixtures were incubated at room temperature for 30 min before loading. Electrophoresis was then carried out with a current of 120 V for 30 min in TAE buffer solution (40 mM Tris-HCl, 1% (v/v) acetic acid, 1 mM EDTA). DNA retardation was visualized by the staining of ethidium bromide with a ultraviolet lamp.
The DNase I protection assay of CSOSA-g-PEI/pDNA complexes was carried out according to previous reports. Briefly, 1 ml of DNase I (2 units) or PBS in DNase/Mg 2 þ digestion buffer (50 mM Tris-Cl, pH 7.6 and 10 mM MgCl2) was added to 4 ml of polyplex solution (weight ratio: 20) or to 0.1 mg of naked plasmid DNA, and incubated at 37 1C with shaking at 100 rpm for 0.5 h. For DNase I inactivation, all samples were treated with 5 ml of EDTA (250 mM) for 10 min and mixed with 1% sodium dodecyl sulfate (SDS) dissolved in 1 M NaOH (pH 7.2) at a final volume of 20 ml. The final samples were incubated for 2 h, and electrophoresis was performed in 1% agarose gel with TAE running buffer for 1 h at 100 V.
Acid-base titration
Acid-base titration assay was performed to estimate the ion-buffer capability of CSOSA, PEI and CSOSA-g-PEI. Briefly, 0.2 mg ml À 1 of each sample solution was prepared in 30 ml 150 mM NaCl solution. First of all, the pH value of each polymer solution was adjusted to 10.0, and then the solution was titrated by 0.1 M HCl over the pH values ranging from 10.0 to 3.0. During titration, the pH value of the mixture was measured using a pH meter.
In vitro cytotoxicity assay
Cytotoxicities of CSOSA-g-PEI and PEI against MCF-7 and HeLa cells were evaluated by MTT assay using Lipofectamine 2000 as the control. Briefly, 10 4 cells were seeded in a 96-well plate with 0.2 ml of growth medium containing 10% FBS and antibiotics. Cells were cultured at 37 1C for 24 h before the addition of filtered test materials. Then, growth medium were replaced by fresh medium containing the desired amount of test materials. The cells were further incubated for 48 h. At the end of incubation, 15 ml 5 mg ml À 1 of MTT solution was added to each well, and the cells were incubated for another 4 h. Next, the medium was removed, and 200 ml of DMSO was added to each well to dissolve the MTT formazan crystals. Plates were shaken for 15 min and the absorbance was read on a microplate reader (Bio-Rad, Model 680, USA) at a wavelength of 570 nm. Survival percentage was calculated as compared with nontreated cells (100% survival).
In vitro transfection experiments
The plasmid DNA (pEGFP-C1 and pGL-3) was used to evaluate the transfection efficiency of CSOSA-g-PEI. Cells were seeded in 24-well plates at a density of 105 cells/well in 1 ml of growth medium. After incubation for 24 h, the media were replaced by 0.5 ml serum-free medium with complex solution (2 mg pDNA) at various weight ratios and additionally incubated for 6 h. Then the medium was exchanged for complete medium containing 10% FBS, and the incubation was allowed to continue for further 7-72 h at 37 1C. For comparison, Lipofectamine 2000 at the weight ratio of 2 was used as the positive control. For GFP assay, the cells expressing GFP were observed by the fluorescence inverted microscope (Leica DMI 4000 B, Leica, Germany), and transfection efficiency was detected by FACScan flow cytometer (LSR II, BD Biosciences, USA). The luciferase assay was performed according to the manufacturer's protocols. Relative light units (RLUs) were measured with a luminometer (Turner Designs Luminometer Model TD-20/20, Promega). Protein quantification was determined by the BCA method, and RLUs were normalized to protein concentration in the cell extracts. Each transfection experiment was carried out in triplicate, and transfection activity was expressed as relative light units.
In vitro VEGF expression experiments BEL7402 (human hepatoma carcinoma) and L02 (immortalized normal human liver cell line) cells were used for VEGF expression experiments. Cells were seeded in 24-well plates at a density of 105 cells/ well in 1 ml of growth medium. After incubation for 24 h, the media were replaced by 0.5 ml serum-free medium with different PEDF formulation (2 mg PEDF) and in addition, incubated for 6 h. Then the medium was exchanged for complete medium containing 10% FBS, and the incubation was allowed to continue for further 48 h at 37 1C.
Real-time PCR (ABI 7500, USA) was performed to quantify mRNA level. Total RNA of the transfection cells was isolated with trizol reagent and reverse transcribed to cDNA with reverse transcriptase at 48 h posttransfection. PCR cycling parameters consisted of denaturation at 95 1C for 3 min, followed by 95 1C for 5 s, 60 1C for 34 s with 40 cycles. Primers for PCR were as follows: VEGF forward (5 0 -GAGAATTCGGCCTCCGAAACCATGAA CTTTCTGCT-3 0 ) and reverse (5 0 -GAGCATGCCCTCCTGCCCGGCTCACCGC-3 0 ), and GAPDH forward (5 0 -AGAAGGCTGGGGCTCATTTG-3 0 ) and reverse (5 0 -AG GGGCCATCCACAGTCTTC-3 0 ).
